BeOne Medicines Ltd. American Depositary Shares
$348.08
Market Cap
$39.38B
Shares Outstanding
113.1M
Primary Exchange
XNAS
Currency
USD
Type
ADRC
IPO Date
Feb 3, 2016
Round Lot
40
Locale
US
Day Open
$342.88
Day High
$349.57
Day Low
$342.88
Volume
356.7K
VWAP
$347.18
Prev Close
$346.50
Transactions
--
Acc. Volume
--
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes mainly with AbbVie and AstraZeneca. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
BeOne Medicines Ltd. American Depositary Shares (ONC) closed the 2026-09-16 session at $348.08, up 0.46% versus the previous close (+1.58). The stock opened at $342.88 and traded between $342.88 and $349.57 during that session. Session trading volume was 357K shares. The volume-weighted average price (VWAP) is $347.18.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes mainly with AbbVie and AstraZeneca. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
BeOne Medicines Ltd. American Depositary Shares has a market capitalization of $39.38 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ONC is listed on the XNAS exchange. The company employs approximately 12,000 people. The recorded listing date is 2016-02-03.
On this page you can find market ONC stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.